The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Marcello F Salgado Filho, MD, Federal University of Juiz de Fora
ClinicalTrials.gov Identifier:
NCT01619436
First received: June 12, 2012
Last updated: June 13, 2012
Last verified: June 2012

June 12, 2012
June 13, 2012
January 2011
January 2012   (final data collection date for primary outcome measure)
sedation [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Clonidine 2 mg/kg IV. assessment sedation with Ransay scale
Same as current
Complete list of historical versions of study NCT01619436 on ClinicalTrials.gov Archive Site
Glycemia [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
clonide 2 mg/kg. assessment the glycemia during CPB.
Same as current
Not Provided
Not Provided
 
The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass
The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass.

The purpose of this study is the randomized blind research of the assessment of the different levels of glycemia during Coronary Artery Bypass Graft (CABG) with cardiopulmonary by-pass (CPB) between clonidine and placebo. As clonidine decrease the inflammatory response during cardiac surgery, the investigators would like to know if the glycemia levels in clondine group will be lower than placebo group.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
  • Glycemia During Coronary Artery Bypass Graft
  • Sedation During Pre-anesthetic Medication
  • Drug: Clonidine
    bolus, clonidine 2 mg/kg IV
  • Drug: Ringer lactato
    1 ML ringer lactato IV, as placebo
  • Active Comparator: clonidine
    clonidine 2 mg/kg IV
    Intervention: Drug: Clonidine
  • Placebo Comparator: ringer lactato 1 ml
    Ringer lactato 1 ml IV as Placebo
    Intervention: Drug: Ringer lactato
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
May 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • elective CABG EF > 40% Sinus ritmy

Exclusion Criteria:

  • precordialgia emergency surgery combinated surgery not agreement
Both
45 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Brazil
 
NCT01619436
0279/03.05.2010
Yes
Marcello F Salgado Filho, MD, Federal University of Juiz de Fora
Federal University of Juiz de Fora
Not Provided
Not Provided
Federal University of Juiz de Fora
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP